Kazia Therapeutics switches ADR depositary to JPMorgan; Nasdaq — listed ADSs stay under KZIA
Kazia Therapeutics appointed JPMorgan Chase Bank as sole depositary for its ADR program, replacing BNY Mellon, effective Sept. 18, 2026. ADSs continue trading on Nasdaq under KZIA, with each ADS representing 500 ordinary shares. No action required for existing ADS holders; transition expected to be seamless with no int